β-Peptide Immunization

Identifying the Pathological Domain of Alpha- Synuclein as a Therapeutic for Parkinson’s Disease

“…However, safety is still a major concern. The major breakthroughs in immunotherapy against AD is attributed to the successful identification of pathological proteins like amyloid beta (Aβ) and Tau, using them as targets for a cure [50,51,52,53,54]. Inspired by these breakthroughs in immunotherapies for AD, scientists have developed immunotherapies targeting alpha synuclein [26,54] since alpha synuclein has been identified as the main pathological protein linked to Parkinson’s Disease [55,56,57].…”

Identifying the Pathological Domain of Alpha- Synuclein as a Therapeutic for Parkinson’s Disease

“…However, safety is still a major concern. The major breakthroughs in immunotherapy against AD is attributed to the successful identification of pathological proteins like amyloid beta (Aβ) and Tau, using them as targets for a cure [50,51,52,53,54]. Inspired by these breakthroughs in immunotherapies for AD, scientists have developed immunotherapies targeting alpha synuclein [26,54] since alpha synuclein has been identified as the main pathological protein linked to Parkinson’s Disease [55,56,57].…”

Use of IQ-Adjusted Norms to Predict Progressive Cognitive Decline in Highly Intelligent Older Individuals.

“…As a result, identifying individuals in preclinical stages before the onset of clinical dementia has been a topic of intense investigation over the past decade. In part, these efforts have been inspired by the clinical availability of palliative treatments (Doody et al, 2001) as well as the promise of disease-modifying agents (Schenk, Seubert, Lieberburg, & Wallace, 2000) that could potentially have a profound impact on functional status and rate of decline if individuals were identified and treated early in the disease course. Although initiatives to develop biological (Diaz-Arrastia & Baskin, 2001) and neuroimaging markers of preclinical AD are under way (Fox et al, 1996;Fox, Warrington, Seiffer, & Rossor, 1998;Jack et al, 1999;Johnson et al, 1998;Killiany et al, 2000Killiany et al, , 2002Reiman et al, 2001;G.…”

Therapeutics and Prion Disease: Can Immunisation or Drugs be Effective?

“…Because of this similarity between AD and prion diseases, similar therapeutic strategies are being tried for both diseases. Both active and passive immunization were proved effective in transgenic mouse models of AD [55,56,57] and the concept was also extended to prion diseases.…”

Identifying the Pathological Domain of Alpha- Synuclein as a Therapeutic for Parkinson’s Disease

“…However, safety is still a major concern. The major breakthroughs in immunotherapy against AD is attributed to the successful identification of pathological proteins like amyloid beta (Aβ) and Tau, using them as targets for a cure [50,51,52,53,54]. Inspired by these breakthroughs in immunotherapies for AD, scientists have developed immunotherapies targeting alpha synuclein [26,54] since alpha synuclein has been identified as the main pathological protein linked to Parkinson’s Disease [55,56,57].…”

Use of IQ-Adjusted Norms to Predict Progressive Cognitive Decline in Highly Intelligent Older Individuals.

“…As a result, identifying individuals in preclinical stages before the onset of clinical dementia has been a topic of intense investigation over the past decade. In part, these efforts have been inspired by the clinical availability of palliative treatments (Doody et al, 2001) as well as the promise of disease-modifying agents (Schenk, Seubert, Lieberburg, & Wallace, 2000) that could potentially have a profound impact on functional status and rate of decline if individuals were identified and treated early in the disease course. Although initiatives to develop biological (Diaz-Arrastia & Baskin, 2001) and neuroimaging markers of preclinical AD are under way (Fox et al, 1996;Fox, Warrington, Seiffer, & Rossor, 1998;Jack et al, 1999;Johnson et al, 1998;Killiany et al, 2000Killiany et al, , 2002Reiman et al, 2001;G.…”

Therapeutics and Prion Disease: Can Immunisation or Drugs be Effective?

“…Because of this similarity between AD and prion diseases, similar therapeutic strategies are being tried for both diseases. Both active and passive immunization were proved effective in transgenic mouse models of AD [55,56,57] and the concept was also extended to prion diseases.…”

Identifying the Pathological Domain of Alpha- Synuclein as a Therapeutic for Parkinson’s Disease

“…However, safety is still a major concern. The major breakthroughs in immunotherapy against AD is attributed to the successful identification of pathological proteins like amyloid beta (Aβ) and Tau, using them as targets for a cure [50,51,52,53,54]. Inspired by these breakthroughs in immunotherapies for AD, scientists have developed immunotherapies targeting alpha synuclein [26,54] since alpha synuclein has been identified as the main pathological protein linked to Parkinson’s Disease [55,56,57].…”

Use of IQ-Adjusted Norms to Predict Progressive Cognitive Decline in Highly Intelligent Older Individuals.

“…As a result, identifying individuals in preclinical stages before the onset of clinical dementia has been a topic of intense investigation over the past decade. In part, these efforts have been inspired by the clinical availability of palliative treatments (Doody et al, 2001) as well as the promise of disease-modifying agents (Schenk, Seubert, Lieberburg, & Wallace, 2000) that could potentially have a profound impact on functional status and rate of decline if individuals were identified and treated early in the disease course. Although initiatives to develop biological (Diaz-Arrastia & Baskin, 2001) and neuroimaging markers of preclinical AD are under way (Fox et al, 1996;Fox, Warrington, Seiffer, & Rossor, 1998;Jack et al, 1999;Johnson et al, 1998;Killiany et al, 2000Killiany et al, , 2002Reiman et al, 2001;G.…”

Therapeutics and Prion Disease: Can Immunisation or Drugs be Effective?

“…Because of this similarity between AD and prion diseases, similar therapeutic strategies are being tried for both diseases. Both active and passive immunization were proved effective in transgenic mouse models of AD [55,56,57] and the concept was also extended to prion diseases.…”